PHN.MI
PHN.MI
IT0005274094
PHARMANUTRA
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±30.4% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).

Beta (Market Relation)
0.18x
Defensive
Volatility (5Y p.a.)
30.4% p.a.
5-Year Horizon
Max Drawdown (5Y)
-50.4%
5-Year Horizon
Sharpe Ratio
0.00
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +42.7%
3 Years 32.1% -38.0% 0.41 +15.7%
5 Years 30.4% -50.4% 0 +2.5%
10 Years 28.8% -50.4% 0.58 —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -50.4% in the extended horizon.
ende